Improve Research Reproducibility A Bio-protocol resource
Concise Method
tooltip

2.1. Trial design

UA Ubiratan Cardinalli Adler
MA Maristela Schiabel Adler
AP Ana Elisa Madureira Padula
LH Livia Mitchiguian Hotta
AC Amarilys de Toledo Cesar
JD José Nelson Martins Diniz
HS Helen de Freitas Santos
EM Edson Zangiacomi Martinez
ask Ask a question
Favorite

A randomized, double-blind, two‐armed (1:1), parallel, single-center, placebo-controlled clinical trial was conducted to test the following hypotheses for mild cases of COVID-19, managed by primary care teams, while undergoing at-home-isolation: H0, the treatment effects of homeopathic Natrum muriaticum LM2 are equal to those of placebo (null hypothesis); H1, the treatment effects of homeopathic Natrum muriaticum LM2 are not equal to those of placebo (alternative hypothesis).

The following guidelines were adopted for this study (namely, COVID-Simile study): the International Council on Harmonisation of Technical Requirements for Registration of Pharmaceuticals for Human Use [10], the Brazilian National Research Ethics Committee for conducting research during COVID-19 [11], the Consolidated Standards of Reporting Trials (CONSORT) [12], and the Reporting Data on Homeopathic Treatments (RedHot) supplement to CONSORT [13].

Copyright and License information:  ©2022 Shanghai Yueyang Hospital Affiliated to Shanghai University of Traditional Chinese Medicine. Published by Elsevier B.V. All rights reserved.
Since January 2020 Elsevier has created a COVID-19 resource centre with free information in English and Mandarin on the novel coronavirus COVID-19. The COVID-19 resource centre is hosted on Elsevier Connect, the company's public news and information website. Elsevier hereby grants permission to make all its COVID-19-related research that is available on the COVID-19 resource centre - including this research content - immediately available in PubMed Central and other publicly funded repositories, such as the WHO COVID database with rights for unrestricted research re-use and analyses in any form or by any means with acknowledgement of the original source. These permissions are granted for free by Elsevier for as long as the COVID-19 resource centre remains active.

Do you have any questions about this protocol?

Post your question to gather feedback from the community. We will also invite the authors of this article to respond.

post Post a Question
0 Q&A